Ann: Strategic Partnership and Lead Program, page-42

Great progress.

Few questions...

* I wonder how long it will take the company before the experiment is repeated?

* Is the second experiment aiming to increase the amount of cells expressing cilia, andthe length of these cilia? If so, how and how long will that take before a read-out becomes available?

* PYC highight they are the majority shareholder and commercialisation partner within Vision Pharma. Is that over 50%?

* The company also highlight, that PYC have granted Vision a non-exclusive license for the use of their CPPs in specific indications in the eye that Vision Pharma wishes to progress into clinical development programs.

This paragraph is what caught my attention....

"Vision is developing a pipeline of other ASO candidates for the treatment of different forms of inherited retinal disease and expects to progress them into the clinicin a staged yet parallel format alongside the lead drug candidate. This pipeline will benefit from the rapid scalability of PYC’s delivery technology in light of the extensive evaluation already performed in the development of Vision’s lead drug program."

And...

PYC can increase its shareholding in Vision in return for providing funding for the progression of Vision Pharma’s programs through IND-enabling and, subsequently, clinica lstudies.

Through a capital raising or/and if they bring a pharma in?

Tony